105 related articles for article (PubMed ID: 31273062)
1. Deletion of the Miz-1 POZ Domain Increases Efficacy of Cytarabine Treatment in T- and B-ALL/Lymphoma Mouse Models.
Ross J; Rashkovan M; Fraszczak J; Joly-Beauparlant C; Vadnais C; Winkler R; Droit A; Kosan C; Möröy T
Cancer Res; 2019 Aug; 79(16):4184-4195. PubMed ID: 31273062
[TBL] [Abstract][Full Text] [Related]
2. Interactions between acute lymphoblastic leukemia and bone marrow stromal cells influence response to therapy.
Tesfai Y; Ford J; Carter KW; Firth MJ; O'Leary RA; Gottardo NG; Cole C; Kees UR
Leuk Res; 2012 Mar; 36(3):299-306. PubMed ID: 21889797
[TBL] [Abstract][Full Text] [Related]
3. BACH2-mediated FOS confers cytarabine resistance via stromal microenvironment alterations in pediatric ALL.
Zhang H; Zhang R; Zheng X; Sun M; Fan J; Fang C; Tian X; Zheng H
Cancer Sci; 2021 Mar; 112(3):1235-1250. PubMed ID: 33393145
[TBL] [Abstract][Full Text] [Related]
4. Miz-1 is required to coordinate the expression of TCRbeta and p53 effector genes at the pre-TCR "beta-selection" checkpoint.
Saba I; Kosan C; Vassen L; Klein-Hitpass L; Möröy T
J Immunol; 2011 Sep; 187(6):2982-92. PubMed ID: 21841135
[TBL] [Abstract][Full Text] [Related]
5. Ink4a and Arf are crucial factors in the determination of the cell of origin and the therapeutic sensitivity of Myc-induced mouse lymphoid tumor.
Sugihara E; Shimizu T; Kojima K; Onishi N; Kai K; Ishizawa J; Nagata K; Hashimoto N; Honda H; Kanno M; Miwa M; Okada S; Andreeff M; Saya H
Oncogene; 2012 Jun; 31(23):2849-61. PubMed ID: 21986948
[TBL] [Abstract][Full Text] [Related]
6. Pediatric-Like Acute Lymphoblastic Leukemia Therapy in Adults With Lymphoblastic Lymphoma: The GRAALL-LYSA LL03 Study.
Lepretre S; Touzart A; Vermeulin T; Picquenot JM; Tanguy-Schmidt A; Salles G; Lamy T; Béné MC; Raffoux E; Huguet F; Chevallier P; Bologna S; Bouabdallah R; Benichou J; Brière J; Moreau A; Tallon-Simon V; Seris S; Graux C; Asnafi V; Ifrah N; Macintyre E; Dombret H
J Clin Oncol; 2016 Feb; 34(6):572-80. PubMed ID: 26644537
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy-induced niche perturbs hematopoietic reconstitution in B-cell acute lymphoblastic leukemia.
Tang C; Li MH; Chen YL; Sun HY; Liu SL; Zheng WW; Zhang MY; Li H; Fu W; Zhang WJ; Liang AB; Tang ZH; Hong DL; Zhou BS; Duan CW
J Exp Clin Cancer Res; 2018 Aug; 37(1):204. PubMed ID: 30157922
[TBL] [Abstract][Full Text] [Related]
8. Combined loss of PUMA and p21 accelerates c-MYC-driven lymphoma development considerably less than loss of one allele of p53.
Valente LJ; Grabow S; Vandenberg CJ; Strasser A; Janic A
Oncogene; 2016 Jul; 35(29):3866-71. PubMed ID: 26640149
[TBL] [Abstract][Full Text] [Related]
9. Miz-1 regulates translation of Trp53 via ribosomal protein L22 in cells undergoing V(D)J recombination.
Rashkovan M; Vadnais C; Ross J; Gigoux M; Suh WK; Gu W; Kosan C; Möröy T
Proc Natl Acad Sci U S A; 2014 Dec; 111(50):E5411-9. PubMed ID: 25468973
[TBL] [Abstract][Full Text] [Related]
10. The role of the transcription factor Miz-1 in lymphocyte development and lymphomagenesis-Binding Myc makes the difference.
Möröy T; Saba I; Kosan C
Semin Immunol; 2011 Oct; 23(5):379-87. PubMed ID: 22000024
[TBL] [Abstract][Full Text] [Related]
11. Highly aggressive lymphomas in adults.
Sweetenham JW
Hematol Oncol Clin North Am; 2008 Oct; 22(5):965-78, ix. PubMed ID: 18954746
[TBL] [Abstract][Full Text] [Related]
12. New genetic abnormalities and treatment response in acute lymphoblastic leukemia.
Meijerink JP; den Boer ML; Pieters R
Semin Hematol; 2009 Jan; 46(1):16-23. PubMed ID: 19100364
[TBL] [Abstract][Full Text] [Related]
13. Lineage classification of childhood acute lymphoblastic leukemia according to the EGIL recommendations: results of the ALL-BFM 2000 trial.
Ratei R; Schabath R; Karawajew L; Zimmermann M; Möricke A; Schrappe M; Ludwig WD
Klin Padiatr; 2013 May; 225 Suppl 1():S34-9. PubMed ID: 23700065
[TBL] [Abstract][Full Text] [Related]
14. Transcription factor miz-1 is required to regulate interleukin-7 receptor signaling at early commitment stages of B cell differentiation.
Kosan C; Saba I; Godmann M; Herold S; Herkert B; Eilers M; Möröy T
Immunity; 2010 Dec; 33(6):917-28. PubMed ID: 21167753
[TBL] [Abstract][Full Text] [Related]
15. Variegated clonality and rapid emergence of new molecular lesions in xenografts of acute lymphoblastic leukemia are associated with drug resistance.
Nowak D; Liem NL; Mossner M; Klaumünzer M; Papa RA; Nowak V; Jann JC; Akagi T; Kawamata N; Okamoto R; Thoennissen NH; Kato M; Sanada M; Hofmann WK; Ogawa S; Marshall GM; Lock RB; Koeffler HP
Exp Hematol; 2015 Jan; 43(1):32-43.e1-35. PubMed ID: 25450514
[TBL] [Abstract][Full Text] [Related]
16. Miz-1 and Max compete to engage c-Myc: implication for the mechanism of inhibition of c-Myc transcriptional activity by Miz-1.
Bédard M; Maltais L; Montagne M; Lavigne P
Proteins; 2017 Feb; 85(2):199-206. PubMed ID: 27859590
[TBL] [Abstract][Full Text] [Related]
17. A beta-sheet interaction interface directs the tetramerisation of the Miz-1 POZ domain.
Stead MA; Trinh CH; Garnett JA; Carr SB; Baron AJ; Edwards TA; Wright SC
J Mol Biol; 2007 Nov; 373(4):820-6. PubMed ID: 17880999
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of Notch Signaling Enhances Chemosensitivity in B-cell Precursor Acute Lymphoblastic Leukemia.
Takam Kamga P; Dal Collo G; Midolo M; Adamo A; Delfino P; Mercuri A; Cesaro S; Mimiola E; Bonifacio M; Andreini A; Chilosi M; Krampera M
Cancer Res; 2019 Feb; 79(3):639-649. PubMed ID: 30563887
[TBL] [Abstract][Full Text] [Related]
19. [Therapeutic strategies for childhood high-risk acute lymphoblastic leukemia].
Lu XT
Beijing Da Xue Xue Bao Yi Xue Ban; 2013 Apr; 45(2):327-32. PubMed ID: 23591360
[TBL] [Abstract][Full Text] [Related]
20. ERG induces a mesenchymal-like state associated with chemoresistance in leukemia cells.
Mochmann LH; Neumann M; von der Heide EK; Nowak V; Kühl AA; Ortiz-Tanchez J; Bock J; Hofmann WK; Baldus CD
Oncotarget; 2014 Jan; 5(2):351-62. PubMed ID: 24504051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
